Metraipolis › archive › dc_8a34e8a17dbb

Preclinical evaluation of TIGIT as a target to enhance efficacy and mitigate T cell exhaustion in multiple myeloma following BCMA-CAR-T therapy — Europe PMC PMID:41419632

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41419632
DOI: 10.1038/s41419-[numero omesso]-w
License (as archived): solo-consultazione
Archived: 2026-11-07T12:37:47.828Z
SHA-256 of the archived text: d2bbe7194235bd699455ce1f3803d242ee29f26e71b584df5b4bb287ad9f71b7
Stable URL of this page: https://metraipolis.com/documento/dc_8a34e8a17dbb

How to cite

Preclinical evaluation of TIGIT as a target to enhance efficacy and mitigate T cell exhaustion in multiple myeloma following BCMA-CAR-T therapy — Europe PMC PMID:41419632 — Europe PMC (en), https://europepmc.org/article/MED/41419632 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8a34e8a17dbb (Metraipolis archive dc_8a34e8a17dbb, sha256 d2bbe7194235bd699455ce1f3803d242ee29f26e71b584df5b4bb287ad9f71b7)

BibTeX

@misc{dc8a34e8a17dbb,
  title = {Preclinical evaluation of TIGIT as a target to enhance efficacy and mitigate T cell exhaustion in multiple myeloma following BCMA-CAR-T therapy — Europe PMC PMID:41419632},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41419632},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8a34e8a17dbb; sha256 d2bbe7194235bd699455ce1f3803d242ee29f26e71b584df5b4bb287ad9f71b7},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41419632. Agents can read the archived copy with the MCP tool read_document.